Pharmexcil urges Industries to get upgrated with changing regulatory norms in China: Ravi Uday Bhaskar

Pharmexcil export of drugs

Last Updated on November 6, 2019 by The Health Master

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged the Indian industry players and exporters to continuously upgrade their knowledge on the changing regularly reforms of medical and pharmaceutical products in China.

As the Chinese regulatory authorities are organising ‘The Chinese Medical Products Regulatory’ meet at Shanghai on November 6, 2019, as part of China International Import Expo (CIIE), Pharmexcil has urged the members of Indian industry players and exporters to take part in the programme and get acquitted with the changing regulatory norms, which would help Indian exporters to explore the Chinese markets.

Already, the Central Drugs Standard Control Organisation (CDSCO) in India and the National Medical Products Administration (NMPA) in China with the support of Department of Commerce and Pharmexcil have been regularly organising various interactive meets in the past between the regulatory, industry players and officials of both countries to understand each other’s needs and requirements. Pharmexcil has urged the industry players to take part in the upcoming Chinese Medical Products regulatory meet, to help understand the Chinese stand point, which would enable Indian players to explore the unexplored highly potential markets of China for the Indian generic medicines.

“Despite of having close proximity with China, Indian generic exporters are not able to explore the highly potential healthcare markets of China for the generic medicine. This is because of lack of proper understanding of their regulatory requirements by the Indian players. If we are in regular touch with the Chinese regulatory authorities it will help us learn their requirements and we can mould accordingly to meet their requirements and thereby we can explore the unexplored Chinese markets,” said Ravi Uday Bhaskar, director general of Pharmexcil.

Adding furthe Ravi Uday Bhaskar said that it is very complex to understand the Chinese regulatory mechanism, because it is constantly changing. In view of this, the DG informed that China Chamber of Commerce for Import and Export of Medicines & Health Products (CCCMHPIE) is organising the Chinese Medical Products Regulatory Forum on November 6, 2019 at National Convention and Exhibition Centre in Shanghai, China.

The forum is expected to witness the presence of industry leaders along with regulatory officials from National Medical Products Administration, National Health Commission and National Health Care Security Administration in China to delve on policy release and interpretation. It is also expected to witness discussions, release and interpretation of policies, and sharing of views among industry experts, government officials and regulators. Elite Chinese and foreign pharmaceutical and medical equipment enterprises are also invited to share their experiences.

In view of the above, Pharmexcil has also urged the Indian players, particularly the exporters to utilise this opportunity and take part in the upcoming programme and get themselves acquainted with the fast chaining Chinese regulatory system so as to help India gain the opportunity to explore the unexplored Chinese markets.